论文部分内容阅读
Ruxolitinib phosphate是由美国Incyte公司研制开发的首个作用于Janus激酶1型和2型(JAK1,JAK2)的抑制剂,于2011年11月16日获美国FDA批准上市,其商品名为Jakafi。这是FDA至今唯一批准的治疗骨髓纤维化(myelofibrosis,MF)的药物。
Ruxolitinib phosphate is the first inhibitor of Janus kinase type 1 and type 2 (JAK1) developed by Incyte Corporation of the United States. It was approved by FDA of the United States on November 16, 2011 under the trade name of Jakafi. This is the only drug approved by the FDA to treat myelofibrosis (MF).